Company intelligence / Profile preview

AccuGenomics

Wilmington, North Carolina, United Statesaccugenomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

AccuGenomics is a commercial-stage company providing multiplexed spike-in quality control standards for next-generation sequencing assays. Their SNAQ™‑SEQ platform improves sensitivity and accuracy of molecular diagnostics, particularly for low-abundance biomarkers such as ctDNA, CNVs, and infectious agents. The technology is used to enhance the analytical performance of clinical sequencing assays[1][3].

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: Device (diagnostic standards and controls)Nucleic acid-based technology (spike-in QC standards for NGS)
Industry: Molecular Diagnostics

Drug pipeline

7 assets

Accukit ctDNA MRD IS

Commercial

Indications: Cancer

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AccuGenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuGenomics.

Explore the full profile